New insider activity at Irhythm Technologies ( (IRTC) ) has taken place on November 4, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
President & CEO Quentin Blackford has recently sold 14,059 shares of Irhythm Technologies stock, amounting to a total value of $2,571,812.
Recent Updates on IRTC stock
In the last 24 hours, iRhythm Technologies has seen several analysts raise their price targets following the company’s strong Q3 2025 earnings report. The earnings call highlighted a 31% year-over-year revenue growth, driven by the success of the Zio AT product line and innovative channel partnerships. Analysts from Truist, Needham, and JPMorgan cited the company’s robust financial performance, increased revenue guidance, and strategic initiatives, such as the expansion of the Zio Monitor and advancements in AI for cardiac arrhythmia detection, as key reasons for the upward revisions. Despite these positive developments, iRhythm faces regulatory challenges due to limited communication with the FDA, impacting their compliance efforts. Overall, the company’s proactive approach to growth and innovation has positioned it well for future success.
Spark’s Take on IRTC Stock
According to Spark, TipRanks’ AI Analyst, IRTC is a Neutral.
Irhythm Technologies’ overall stock score is driven by strong earnings call performance and positive technical indicators. However, significant financial performance challenges, particularly high leverage and negative profitability, weigh heavily on the score. The valuation is also a concern due to the negative P/E ratio.
To see Spark’s full report on IRTC stock, click here.
More about Irhythm Technologies
YTD Price Performance: 106.84%
Average Trading Volume: 407,388
Technical Sentiment Signal: Buy
Current Market Cap: $5.96B